Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium-99m sestamibi
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Technetium-99m sestamibi is a radiopharmaceutical diagnostic agent used primarily in nuclear medicine for myocardial perfusion imaging to detect coronary artery disease and evaluate myocardial function. It consists of the radioisotope technetium‑99m complexed with six methoxyisobutylisonitrile (MIBI) ligands. After intravenous injection, it is taken up by tissues with high mitochondrial content and negative plasma membrane potentials, such as myocardium, parathyroid tissue, and certain breast tissues. Its uptake in myocardial cells reflects blood flow and mitochondrial activity; areas of reduced uptake indicate ischemia or infarction. The compound is also used for preoperative localization of parathyroid adenomas in hyperparathyroidism and as an adjunct in breast cancer diagnostics through scintimammography or breast-specific gamma imaging[1][2][5][6][8].
- Brand names
- CardioliteDraximage Sestamibi (Canada)Miraluma (for breast imaging)
- Other names
- MIBI scansestaMIBI
Beyond the preview
Go deeper on technetium-99m sestamibi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium-99m sestamibi.